Eyegate, Valeant deal

EyeGate granted Valeant exclusive, worldwide rights to manufacture and commercialize EGP-437 in combination with the EyeGate II Drug Delivery System to treat postoperative pain and inflammation in ocular surgery patients. The dexamethasone phosphate ophthalmic solution is in Phase Ib/IIa testing for the indication. EyeGate will be responsible for all development and regulatory costs in the U.S. Valeant will be responsible for all development and regulatory costs outside of the U.S. ...